Imatinib Teva (Imatinib)

Imatinib blocks the activity of specific tyrosine kinases such as BCR‑ABL, KIT and PDGFR. By occupying the ATP‑binding pocket of these enzymes, it prevents downstream signaling that drives uncontrolled cell growth, leading to reduced proliferation of malignant cells.

The dose of Imatinib Teva is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, weight, renal and hepatic function, and other individual factors. Only a qualified health professional should set the dosing regimen.

Safety data for Imatinib Teva in pregnancy and lactation are limited. The drug may pose risks to the fetus or infant, and its use is generally avoided unless the potential benefit justifies the risk. Patients should discuss reproductive plans with their healthcare provider.

To request Imatinib Teva, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib Teva belongs to the first‑generation tyrosine kinase inhibitor class and directly targets BCR‑ABL. Newer agents such as dasatinib or nilotinib are second‑generation inhibitors with broader activity against some resistant mutations, but Imatinib remains a standard first‑line option due to its established efficacy and safety profile.

Imatinib Teva should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability and potency.

Imatinib Teva is taken orally, usually with a glass of water. It can be swallowed with or without food, but patients should follow the specific instructions provided by their prescriber to ensure consistent absorption.

Serious risks include severe neutropenia or leukopenia, which can increase infection risk, hepatotoxicity marked by elevated liver enzymes, and cardiac complications such as reduced left‑ventricular function. Patients should be monitored regularly for these events.

Individuals with known hypersensitivity to imatinib or any of its excipients should avoid the product. Caution is also advised for patients with pre‑existing severe liver impairment, uncontrolled heart failure, or those taking contraindicated strong CYP3A4 modulators.